Ignite Creation Date:
2024-05-05 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00350038
Status:
COMPLETED
Last Update Posted:
2008-01-23
First Post:
2006-07-07
Brief Title:
Irbesartan Ciprofibrate and Their Combination Onto the Endothelial Functions
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Investigations of the Effects of Aprovel Lipanor and Their Combination Onto the Endothelial Functions of Dyslipidemic Patients Measure by Laser Doppler Flow-Metry
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect could improve the endothelial functions andor could affect the atherogenic small-dense LDL- oxydized LDL concentrations onto the paraoxinase activity and on the CRP and insulin levels
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None